全文获取类型
收费全文 | 197922篇 |
免费 | 20056篇 |
国内免费 | 8148篇 |
专业分类
耳鼻咽喉 | 761篇 |
儿科学 | 4644篇 |
妇产科学 | 1160篇 |
基础医学 | 16069篇 |
口腔科学 | 2120篇 |
临床医学 | 25139篇 |
内科学 | 27391篇 |
皮肤病学 | 1036篇 |
神经病学 | 11858篇 |
特种医学 | 8839篇 |
外国民族医学 | 103篇 |
外科学 | 24282篇 |
综合类 | 37784篇 |
现状与发展 | 28篇 |
一般理论 | 2篇 |
预防医学 | 13930篇 |
眼科学 | 2167篇 |
药学 | 19239篇 |
201篇 | |
中国医学 | 10490篇 |
肿瘤学 | 18883篇 |
出版年
2024年 | 305篇 |
2023年 | 3673篇 |
2022年 | 5073篇 |
2021年 | 9483篇 |
2020年 | 9031篇 |
2019年 | 7004篇 |
2018年 | 6816篇 |
2017年 | 7749篇 |
2016年 | 8136篇 |
2015年 | 8149篇 |
2014年 | 13279篇 |
2013年 | 14892篇 |
2012年 | 12253篇 |
2011年 | 13486篇 |
2010年 | 10800篇 |
2009年 | 10319篇 |
2008年 | 10240篇 |
2007年 | 10511篇 |
2006年 | 9525篇 |
2005年 | 8588篇 |
2004年 | 7046篇 |
2003年 | 6323篇 |
2002年 | 4759篇 |
2001年 | 4248篇 |
2000年 | 3603篇 |
1999年 | 2808篇 |
1998年 | 2266篇 |
1997年 | 2099篇 |
1996年 | 1758篇 |
1995年 | 1679篇 |
1994年 | 1468篇 |
1993年 | 1123篇 |
1992年 | 1075篇 |
1991年 | 839篇 |
1990年 | 745篇 |
1989年 | 678篇 |
1988年 | 582篇 |
1987年 | 516篇 |
1986年 | 445篇 |
1985年 | 586篇 |
1984年 | 404篇 |
1983年 | 275篇 |
1982年 | 305篇 |
1981年 | 281篇 |
1980年 | 239篇 |
1979年 | 191篇 |
1978年 | 127篇 |
1977年 | 108篇 |
1976年 | 87篇 |
1975年 | 61篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献
75.
目的研究利用经聚乙烯亚胺(PEI)钝化的荧光碳点(CD)装载阿霉素(DOX)进行药物递送,旨在增加DOX对非小细胞肺癌的治疗作用,减少DOX的心肌毒性。 方法通过一步微波加热法将甘油和PEI的混合物制备成CD-PEI,并通过静电效应将DOX装载至CD-PEI。采用CCK8实验检测CD-PEI-DOX对非小细胞肺癌细胞A549的增殖能力的影响;Transwell实验评估CD-PEI-DOX对A549细胞迁移侵袭能力的影响;最后通过体内动物实验评估CD-PEI-DOX的心肌毒性以及对非小细胞肺癌皮下肿瘤生长的抑制效果。 结果体外细胞实验证实,对比单纯的DOX处理组,CD-PEI-DOX对非小细胞肺癌A549细胞增殖、迁移侵袭能力的抑制作用更为显著。体内实验证实,CD-PEI-DOX纳米复合物治疗组小鼠心肌细胞结构完整,并且能有效抑制小鼠皮下肺癌肿瘤的生长。 结论经PEI钝化的荧光碳点负载阿霉素能显著提高DOX对非小细胞肺癌的治疗效果,并减少DOX对心脏的毒性作用。运用CD-PEI纳米颗粒改善化疗药物递送的治疗方案取得了初步证实,这可为肺癌化学治疗提供新思路,具有广大的临床应用前景。 相似文献
76.
77.
儿童哮喘与慢性阻塞性肺疾病(COPD)是儿童期与成人期常见的存在气流受限的慢性气道疾病。研究发现,儿童哮喘会增加成年期罹患COPD的风险,而肺功能变化是预测COPD患病风险的重要指标。针对哮喘患儿建立长期肺功能监测管理,对于评估其成年后存在不可逆气道阻塞的风险有重要意义。文章综述儿童哮喘与COPD相关的研究进展。 相似文献
78.
ObjectivesThe study aimed to analyse the association between Sports-Related Concussion (SRC) and Subsequent Musculoskeletal Injury (MSK) in United Kingdom university-aged rugby union players whilst considering the effects of sex, athlete playing position and injury location.DesignRetrospective cohort study. A period of 365 days with 0–90, 91–180 and 181–365 days sub-periods was analysed for the following variables; MSK injury incidence, occurrence, severity, injury location, playing position and sex.SettingInjury data was collected from the Sports Development Centre database at Loughborough University.ParticipantsA total of 408 injuries in 181 athletes (55 females and 126 males) were included.ResultsThe MSK injury incidence of SRC group was significantly higher than control and higher post-SRC than pre-SRC period over a 365-day period (p=0.012 and p=0.034, respectively). The odds ratios of MSK injury incidence between groups and between periods were 1.62 (95% CI, 1.10–2.25) and 1.57 (95% CI ,1.08–2.29). A SRC was not associated with a greater time loss from a subsequent MSK injury or a specific MSK injury location.ConclusionsAthletes with a second recorded injury were more likely to sustain a MSK injury if they had experienced SRC, however, there was no indication a SRC resulted in greater time loss from a MSK injury. 相似文献
79.
肺癌是我国死亡率最高的恶性肿瘤。肌少症在肺癌患者中发病率较高,且近年来越来越多的研究显示肌少症对肺癌患者预后预测具有一定价值。本文就肌少症的诊断、肺癌与肌少症的关系以及肌少症对肺癌患者预后预测、干预治疗等方面的研究进行综述。 相似文献
80.
Jerzy Klijanienko MD PhD Béatrix Cochand-Priollet MD PhD Wiktoria Król-Cieciorowska Michał Jeleń MD PhD Danijela Vrdoljak-Mozetič MD PhD 《Cancer cytopathology》2022,130(7):488-490
The 43rd European Congress of Cytology in Wrocław, Poland, was held as a hybrid meeting in the Fall of 2021. After nearly 2 years without in-person cytology conferences, the 43rd Congress represents 1 of the first major international scientific meetings to occur during the severe acute respiratory syndrome-coronavirus 2 pandemic. Since March 2020, the pandemic situation substantially modified the organization of scientific meetings because of both domestic and international travel restrictions, new health standards, and concern among participants, resulting in new alternative forms of virtual conferencing. Cancer (Cancer Cytopathol) 2022;130:000-000. ; 相似文献